The board has set the repurchase price at 100 percent of the share's quotient value, roughly SEK 0.55 per share. This operation is conditional upon the successful subscription and payment by Svenska Handelsbanken AB. Executions are scheduled to take place between July 16 and November 6, 2026.
Once the repurchase is finalized, Sobi intends to convert these class C shares into common shares. This move will increase the company’s total holdings of its own common stock to 10,290,974 shares. Currently, the biopharma firm holds 10,067,297 common shares and zero class C shares.

Comments (0)
No comments yet. Be the first!